| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80053 |
Comprehensive metabolic panel |
19,635 |
16,823 |
$1.87M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
27,535 |
24,781 |
$1.51M |
| J7030 |
Infusion, normal saline solution , 1000 cc |
7,871 |
6,301 |
$1.22M |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
3,548 |
3,307 |
$991K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,116 |
5,749 |
$960K |
| 81001 |
|
14,220 |
12,583 |
$656K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,380 |
3,171 |
$497K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,019 |
3,229 |
$276K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,385 |
2,273 |
$254K |
| 87081 |
|
1,718 |
1,678 |
$194K |
| 71046 |
Radiologic examination, chest; 2 views |
4,577 |
4,298 |
$166K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,452 |
3,105 |
$135K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,263 |
3,123 |
$134K |
| 87075 |
|
1,103 |
1,074 |
$130K |
| 36415 |
Collection of venous blood by venipuncture |
1,680 |
1,560 |
$129K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,359 |
1,302 |
$125K |
| 73630 |
|
1,076 |
1,015 |
$107K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,219 |
2,924 |
$105K |
| 73610 |
|
712 |
678 |
$92K |
| 81025 |
|
6,656 |
6,031 |
$87K |
| 71045 |
Radiologic examination, chest; single view |
6,645 |
5,968 |
$81K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
22,058 |
18,672 |
$80K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,909 |
2,699 |
$71K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
927 |
827 |
$66K |
| 73130 |
|
458 |
439 |
$65K |
| 73562 |
|
808 |
774 |
$62K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,106 |
8,266 |
$52K |
| 81003 |
|
984 |
904 |
$51K |
| 86780 |
|
923 |
901 |
$50K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,675 |
2,600 |
$35K |
| 73030 |
|
389 |
368 |
$33K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,308 |
4,898 |
$32K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,019 |
2,123 |
$30K |
| 73110 |
|
192 |
181 |
$27K |
| 84439 |
|
1,059 |
1,035 |
$25K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,641 |
8,306 |
$24K |
| 87077 |
|
1,692 |
1,593 |
$23K |
| 81015 |
|
333 |
312 |
$22K |
| 72100 |
|
534 |
502 |
$21K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,948 |
4,457 |
$17K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
6,847 |
6,111 |
$17K |
| 83655 |
|
572 |
566 |
$17K |
| 84484 |
|
7,281 |
5,322 |
$16K |
| 80061 |
Lipid panel |
2,275 |
2,174 |
$13K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,939 |
2,814 |
$13K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,784 |
1,699 |
$13K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
602 |
567 |
$11K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
364 |
354 |
$10K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
47 |
42 |
$10K |
| 83690 |
|
7,854 |
6,960 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,614 |
1,540 |
$9K |
| 76830 |
Ultrasound, transvaginal |
52 |
50 |
$8K |
| 83880 |
|
3,145 |
2,703 |
$6K |
| 84702 |
|
324 |
247 |
$6K |
| 87581 |
|
108 |
108 |
$6K |
| 87040 |
|
1,890 |
1,195 |
$5K |
| 87807 |
|
227 |
217 |
$5K |
| 73502 |
|
138 |
129 |
$5K |
| J7050 |
Infusion, normal saline solution, 250 cc |
118 |
91 |
$4K |
| 85027 |
|
1,499 |
1,241 |
$3K |
| 86803 |
|
780 |
761 |
$3K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
26 |
26 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
27 |
25 |
$3K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
31 |
28 |
$2K |
| 82728 |
|
153 |
148 |
$2K |
| 87210 |
|
161 |
157 |
$2K |
| 73080 |
|
15 |
15 |
$2K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
51 |
49 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
30 |
30 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,443 |
2,243 |
$2K |
| 74021 |
|
39 |
39 |
$1K |
| 83735 |
|
3,822 |
3,224 |
$1K |
| 83605 |
|
2,524 |
2,018 |
$1K |
| 87340 |
|
826 |
814 |
$1K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,870 |
2,626 |
$1K |
| 85610 |
|
2,523 |
2,219 |
$1K |
| 82043 |
|
189 |
170 |
$907.09 |
| G0378 |
Hospital observation service, per hour |
563 |
422 |
$905.48 |
| 87140 |
|
704 |
646 |
$860.01 |
| 86308 |
|
15 |
13 |
$850.47 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,408 |
3,008 |
$818.56 |
| 73590 |
|
13 |
12 |
$769.69 |
| 85379 |
|
484 |
462 |
$723.87 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
107 |
103 |
$722.05 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
872 |
849 |
$680.58 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,067 |
1,628 |
$657.72 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
158 |
52 |
$602.52 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
576 |
555 |
$402.30 |
| 82570 |
|
300 |
266 |
$367.75 |
| 86850 |
|
134 |
133 |
$354.44 |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
54 |
50 |
$335.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
81 |
80 |
$285.81 |
| 82272 |
|
28 |
27 |
$212.47 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,350 |
2,213 |
$187.85 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,198 |
3,040 |
$102.26 |
| 85652 |
|
114 |
108 |
$58.41 |
| 85014 |
|
183 |
176 |
$57.48 |
| 86140 |
|
901 |
797 |
$56.86 |
| 80143 |
|
17 |
16 |
$53.81 |
| 85018 |
|
368 |
355 |
$48.67 |
| 86900 |
|
345 |
313 |
$24.28 |
| 85730 |
|
2,222 |
2,033 |
$17.78 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,181 |
3,612 |
$10.46 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,479 |
3,966 |
$5.65 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,522 |
1,391 |
$1.93 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
879 |
623 |
$1.14 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,823 |
1,522 |
$0.23 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
697 |
653 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,094 |
1,018 |
$0.00 |
| J3490 |
Unclassified drugs |
1,551 |
1,308 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12 |
12 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
404 |
282 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
61 |
51 |
$0.00 |
| 82077 |
|
1,281 |
1,123 |
$0.00 |
| 86901 |
|
346 |
313 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
46 |
27 |
$0.00 |
| A9270 |
Non-covered item or service |
928 |
812 |
$0.00 |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
715 |
683 |
$0.00 |
| 96376 |
|
273 |
248 |
$0.00 |
| 82803 |
|
178 |
155 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
45 |
44 |
$0.00 |
| 82550 |
|
95 |
76 |
$0.00 |
| 86762 |
|
67 |
66 |
$0.00 |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
39 |
38 |
$0.00 |
| 80320 |
|
49 |
44 |
$0.00 |
| 82607 |
|
12 |
12 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
69 |
65 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
60 |
52 |
$0.00 |
| 86738 |
|
12 |
12 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
16 |
12 |
$0.00 |
| 87186 |
|
1,982 |
1,809 |
$0.00 |
| 90715 |
|
70 |
67 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
674 |
600 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
153 |
138 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
2,118 |
1,671 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
205 |
180 |
$0.00 |
| 83540 |
|
13 |
13 |
$0.00 |
| G0659 |
Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes |
329 |
306 |
$0.00 |
| 84466 |
|
14 |
14 |
$0.00 |
| 80179 |
|
15 |
14 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
16 |
16 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
13 |
12 |
$0.00 |